MDNA.TO
Medicenna Therapeutics Corp. [MDNA.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MDNA.TO Stock Summary
Top 10 Correlated ETFs
MDNA.TO
Top 10 Correlated Stocks
MDNA.TO
In the News
MDNA.TO Financial details
Company Rating
Neutral
Market Cap
136.49M
Income
-15.42M
Revenue
0
Book val./share
0.27
Cash/share
0.31
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
25 Jun 2024
P/E
-2.62
Forward P/E
-
PEG
0.55
P/S
-
P/B
1.29
P/C
5.58
P/FCF
-2.27
Quick Ratio
7.03
Current Ratio
7.49
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.22
EPS next Y
-
EPS next Q
-
EPS this Y
-105.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
33.64%
-
-
-
-
SMA20
100%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-42%
ROE
-41%
ROC
-0.7%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.215-2.1
52W High
-
52W Low
-
RSI
55
Rel Volume
0.5
Avg Volume
132.96K
Volume
66.6K
Perf Week
-11.28%
Perf Month
54.46%
Perf Quarter
517.86%
Perf Half Y
321.95%
-
-
-
-
Beta
1.332
-
-
Volatility
0.09%, 0.22%
Prev Close
0%
Price
1.73
Change
-5.98%
MDNA.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.18 | -0.26 | -0.35 | -0.42 | 0.02 | |
| Operating cash flow per share | -0.31 | -0.28 | -0.31 | -0.43 | -0.2 | |
| Free cash flow per share | -0.31 | -0.28 | -0.31 | -0.43 | -0.2 | |
| Cash per share | 0.09 | 1.18 | 0.81 | 0.38 | 0.52 | |
| Book value per share | 0.1 | 1.13 | 0.77 | 0.38 | 0.46 | |
| Tangible book value per share | 0.1 | 1.13 | 0.77 | 0.38 | 0.45 | |
| Share holders equity per share | 0.1 | 1.13 | 0.77 | 0.38 | 0.46 | |
| Interest debt per share | 0 | 0 | 0 | 0 | -0.18 | |
| Market cap | 19.51M | 114.84M | 253.77M | 89.57M | 56.97M | |
| Enterprise value | 17.14M | 92.21M | 223.43M | 69.04M | 23.37M | |
| P/E ratio | -4.14 | -13.82 | -14.77 | -3.96 | 36.82 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -2.43 | -12.82 | -16.57 | -3.8 | -4.5 | |
| PFCF ratio | -2.43 | -12.82 | -16.57 | -3.8 | -4.5 | |
| P/B Ratio | 7.46 | 3.18 | 6.65 | 4.3 | 1.93 | |
| PTB ratio | 7.46 | 3.18 | 6.65 | 4.3 | 1.93 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.62 | -11.25 | -13.03 | -3.1 | -1.08 | |
| EV to operating cash flow | -2.13 | -10.3 | -14.59 | -2.93 | -1.85 | |
| EV to free cash flow | -2.13 | -10.3 | -14.59 | -2.93 | -1.85 | |
| Earnings yield | -0.24 | -0.07 | -0.07 | -0.25 | 0.03 | |
| Free cash flow yield | -0.41 | -0.08 | -0.06 | -0.26 | -0.22 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.5 | 2.76 | 1.77 | 0.92 | 1.55 | |
| Current ratio | 2.13 | 20.85 | 10.26 | 8.92 | 9.58 | |
| Interest coverage | 0 | 0 | 0 | -323.19 | 1.87 | |
| Income quality | 1.71 | 1.08 | 0.89 | 1.04 | 1.26 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.65 | 2.58 | 2.45 | 1.9 | 0.49 | |
| ROIC | -1.81 | -0.23 | -0.45 | -1.07 | 0.11 | |
| Return on tangible assets | -0.92 | -0.22 | -0.41 | -0.97 | 0.04 | |
| Graham Net | 0.06 | 1.13 | 0.74 | 0.35 | 0.42 | |
| Working capital | 2.71M | 36.04M | 38.04M | 20.77M | 32.59M | |
| Tangible asset value | 2.54M | 36.07M | 38.07M | 20.77M | 29.43M | |
| Net current asset value | 2.54M | 36.01M | 38.04M | 20.77M | 29.43M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 1.32M | 1.27M | 234.15K | 859K | 1.08M | |
| Average payables | 839.66K | 629.13K | 1.35M | 1.96M | 1.64M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 42.94K | 21.1K | 20.49K | 16.06K | 118.04K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0.02 | 0.02 | 0.02 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.8 | -0.23 | -0.45 | -1.09 | 0.05 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.02 | -0.06 | -0.04 | -0.05 | -0.07 | |
| Operating cash flow per share | -0.05 | -0.03 | -0.05 | -0.06 | -0.06 | |
| Free cash flow per share | -0.05 | -0.03 | -0.05 | -0.06 | -0.06 | |
| Cash per share | 0.52 | 0.48 | 0.43 | 0.37 | 0.31 | |
| Book value per share | 0.48 | 0.42 | 0.39 | 0.34 | 0.27 | |
| Tangible book value per share | 0.48 | 0.42 | 0.39 | 0.34 | 0.27 | |
| Share holders equity per share | 0.48 | 0.42 | 0.39 | 0.34 | 0.27 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 44.57M | 61.28M | 44.57M | 27.85M | 29.25M | |
| Enterprise value | 8.41M | 27.68M | 14.95M | 2.17M | 7.49M | |
| P/E ratio | -9.77 | -3.97 | -3.89 | -1.87 | -1.47 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -12.19 | -26.75 | -12.85 | -7.1 | -7.26 | |
| PFCF ratio | -12.19 | -26.75 | -12.85 | -7.1 | -7.26 | |
| P/B Ratio | 1.34 | 2.08 | 1.66 | 1.19 | 1.57 | |
| PTB ratio | 1.34 | 2.08 | 1.66 | 1.19 | 1.57 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.01 | -16.26 | -2.62 | -0.32 | -1.57 | |
| EV to operating cash flow | -2.3 | -12.08 | -4.31 | -0.55 | -1.86 | |
| EV to free cash flow | -2.3 | -12.08 | -4.31 | -0.55 | -1.86 | |
| Earnings yield | -0.03 | -0.06 | -0.06 | -0.13 | -0.17 | |
| Free cash flow yield | -0.08 | -0.04 | -0.08 | -0.14 | -0.14 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 4.33 | 19.73 | 5.19 | 3.77 | 4.56 | |
| Current ratio | 12.75 | 9.58 | 9.74 | 7.49 | 5.77 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 3.21 | 0.59 | 1.21 | 1.05 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.42 | 0.73 | 0.6 | 0.64 | 0.66 | |
| ROIC | 0.58 | -0.07 | 0 | -0.16 | -0.26 | |
| Return on tangible assets | -0.03 | -0.11 | -0.09 | -0.13 | -0.21 | |
| Graham Net | 0.45 | 0.39 | 0.37 | 0.31 | 0.25 | |
| Working capital | 35.12M | 32.59M | 28.25M | 23.99M | 19.18M | |
| Tangible asset value | 33.16M | 29.43M | 26.84M | 23.38M | 18.57M | |
| Net current asset value | 33.16M | 29.43M | 26.84M | 23.38M | 18.57M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 164K | 517K | 845K | 570.5K | 354.5K | |
| Average payables | 2.96K | 809.99K | 810.12K | 1.62K | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 134.51 | 145.53K | 290.97 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.67 | 0 | 0.31 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.03 | -0.13 | -0.11 | -0.16 | -0.27 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MDNA.TO Frequently Asked Questions
What is Medicenna Therapeutics Corp. stock symbol ?
Medicenna Therapeutics Corp. is a CA stock , located in Toronto of On and trading under the symbol MDNA.TO
What is Medicenna Therapeutics Corp. stock quote today ?
Medicenna Therapeutics Corp. stock price is $1.73 today.
Is Medicenna Therapeutics Corp. stock public?
Yes, Medicenna Therapeutics Corp. is a publicly traded company.
Company Profile
- Volume Average 132.96K
- Market Capitalization 136.49M
- Employee 16
- CEO Dr. Fahar Merchant Ph.D.
- Headquarters Toronto,ON,CA
- IPO Date 2017-03-08
-
Website
https://www.medicenna.com 
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
